Search
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalMirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). NF1 is an autosomal-dominant genetic condit...
Tolterodine
go.drugbank.com/drugs/DB01036ApprovedInvestigationalTolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalRenal complications are major comorbidities that limit the [DB00437] therapy as dose reductions are recommended. … Xanthine oxidase inhibitors are classified into two groups; purine analogs such as [DB00437] and [DB05262], and non-purine agents which includes topiroxostat.
Clidinium
go.drugbank.com/drugs/DB00771ApprovedClidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylc...
Demeclocycline
go.drugbank.com/drugs/DB00618ApprovedA tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Etrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigationalEtrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P1,4,5 with no detectable activity on S1P2 and S1P3 receptors. S1P receptors are membrane-derived lysophospholipid sig...
Fluoride ion F-18
go.drugbank.com/drugs/DB09398ApprovedInvestigationalSodium Fluoride F 18 Injection is a positron emitting radiopharmaceutical, no-carrier added. It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is...
ISS-1018
go.drugbank.com/drugs/DB05463InvestigationalISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.
Canakinumab
go.drugbank.com/drugs/DB06168ApprovedInvestigationalwell as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). … for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as
Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions. … [A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes